<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00684255</url>
  </required_header>
  <id_info>
    <org_study_id>AAAB1324</org_study_id>
    <secondary_id>CHNY-01-511</secondary_id>
    <nct_id>NCT00684255</nct_id>
  </id_info>
  <brief_title>Reduced Intensity Transplant in Medically Refractory Systemic Lupus Erythematosus (SLE) and Systemic Sclerosis (SSc)</brief_title>
  <official_title>Reduced Intensity Conditioning And Allogeneic Stem Cell Transplantation in Patients With Medically Refractory Systemic Lupus Erythematosus and Medically Refractory Systemic Sclerosis (SSc)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York Medical College</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New York Medical College</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if a reduced intensity (RI) (non-myeloablative)
      chemoimmunotherapy followed by Allogeneic Stem Cell Transplantation AlloSCT (matched family
      donors and matched unrelated cord blood donors) will be well tolerated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is to test whether a reduced intensity will result in a high degree of mixed or complete
      donor chimerism and stabilization of autoimmune disease in a select group of patients with
      medically refractory SLE or SSc.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    inactive
  </why_stopped>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity</measure>
    <time_frame>1 year</time_frame>
    <description>Toxicity associated with reduced intensity regimen of fludarabine/busulfan and Campath followed by allogeneic stem cell transplant in patients with medically refractory Systemic Lupus Erythematosus (SLE) or SSc is measured.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Chimerism</measure>
    <time_frame>1 year</time_frame>
    <description>Percentage(%) of mixed and/or complete donor chimerism has been measured at different time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune Reconstitution.</measure>
    <time_frame>1 year</time_frame>
    <description>Peripheral blood for immune reconstitution for T-cell, B-cell and NK cells to be obtained for measurement of cell.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free and Overall Survival.</measure>
    <time_frame>1 year</time_frame>
    <description>Probability of progression free and overall survival will be measured.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <condition>Systemic Sclerosis</condition>
  <arm_group>
    <arm_group_label>Reduced Intensity Regimen for Refractory SLE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RI regimen of fludarabine/busulfan and Alemtuzumab (FBA) followed by AlloSCT in selected patients with medically refractory Systemic Lupus Erythematosus (SLE).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reduced Intensity Regimen for SSc</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RI regimen of fludarabine/busulfan and Alemtuzumab (FBA) followed by AlloSCT in selected patients with Systemic Sclerosis (SSc).</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Reduced Intensity Allogeneic Transplant</intervention_name>
    <description>Eeduced intensity allogeneic stem cell transplantation with a fludarabine/busulfan/alemtuzumab conditioning regimen is anticipated to result in mixed and/or complete donor chimerism and potentially alter the natural history and outcome of patients with medically refractory Systemic Lupus Erythematosus (SLE) or Systemic Sclerosis (SSc).</description>
    <arm_group_label>Reduced Intensity Regimen for Refractory SLE</arm_group_label>
    <arm_group_label>Reduced Intensity Regimen for SSc</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Fludarabine 30 mg/m2 Day -7, -6, -5, -4, -3, -2</description>
    <arm_group_label>Reduced Intensity Regimen for Refractory SLE</arm_group_label>
    <arm_group_label>Reduced Intensity Regimen for SSc</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>Busulfan 3.2 mg/kg Days _8, -7, -6, -5</description>
    <arm_group_label>Reduced Intensity Regimen for Refractory SLE</arm_group_label>
    <arm_group_label>Reduced Intensity Regimen for SSc</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Campath</intervention_name>
    <description>Campath: 2 mg/m2 Day -5; 6 mg/m2 Day -4, -3; 20 mg/m2 Day -2</description>
    <arm_group_label>Reduced Intensity Regimen for Refractory SLE</arm_group_label>
    <arm_group_label>Reduced Intensity Regimen for SSc</arm_group_label>
    <other_name>Alemtuzumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diffuse Systemic Sclerosis and variants as per ACR criteria

          -  Medically refractory disease

          -  Adequate Organ Function - Pulmonary function

          -  Renal function, Cardiac function defined as:

          -  SGOT (AST) or SGPT (ALT) &lt;5 x upper limit of normal

          -  Diagnosis of SLE - Medically refractory disease

        Exclusion Criteria:

          -  Karnofsky/Lansky &lt;60%
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mitchell Cairo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.childrensnyp.org</url>
    <description>(Click on &quot;Morgan Stanley Children's Hospital&quot; and then &quot;Clinical Services&quot; and then &quot;Blood &amp; Marrow Transplantation&quot;)</description>
  </link>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 22, 2008</study_first_submitted>
  <study_first_submitted_qc>May 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2008</study_first_posted>
  <results_first_submitted>December 22, 2008</results_first_submitted>
  <results_first_submitted_qc>November 23, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 2, 2009</results_first_posted>
  <last_update_submitted>February 6, 2014</last_update_submitted>
  <last_update_submitted_qc>February 6, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>New York Medical College</investigator_affiliation>
    <investigator_full_name>Mitchell Cairo</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Autoimmune Disease</keyword>
  <keyword>Reduced Intensity Transplant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Alemtuzumab</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study closed due to low accrual.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Reduced Intensity Regimen SSc</title>
          <description>Reduced Intensity Regimen Medically Refractory Systemic Sclerosis (SSc)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Systemic Sclerosis (SSc)</title>
          <description>Reduced Intensity Regimen Medically Refractory Systemic Sclerosis (SSc)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Subjects 7-17yrs will be enrolled</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Toxicity</title>
        <description>Toxicity associated with reduced intensity regimen of fludarabine/busulfan and Campath followed by allogeneic stem cell transplant in patients with medically refractory Systemic Lupus Erythematosus (SLE) or SSc is measured.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Medically Refractory Systemic Lupus Erythematosus (SLE)</title>
            <description>Reduced Intensity Regimen of Fludarabine/Busulfan and Campath Followed by alloSCT in patients with Medically Refractory Systemic Lupus Erythematosus (SLE)</description>
          </group>
          <group group_id="O2">
            <title>Systemic Sclerosis (SSc)</title>
            <description>Reduced Intensity Regimen of Fludarabine/Busulfan and Campath Followed by alloSCT in patients with Systemic Sclerosis (SSc)</description>
          </group>
        </group_list>
        <measure>
          <title>Toxicity</title>
          <description>Toxicity associated with reduced intensity regimen of fludarabine/busulfan and Campath followed by allogeneic stem cell transplant in patients with medically refractory Systemic Lupus Erythematosus (SLE) or SSc is measured.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Chimerism</title>
        <description>Percentage(%) of mixed and/or complete donor chimerism has been measured at different time points.</description>
        <time_frame>1 year</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immune Reconstitution.</title>
        <description>Peripheral blood for immune reconstitution for T-cell, B-cell and NK cells to be obtained for measurement of cell.</description>
        <time_frame>1 year</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free and Overall Survival.</title>
        <description>Probability of progression free and overall survival will be measured.</description>
        <time_frame>1 year</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Reduced Intensity Regimen SSc</title>
          <description>Reduced Intensity Regimen Medically Refractory Systemic Sclerosis (SSc)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study closed due to low accrual. Did not meet enrollment goals.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Mitchell S. Cairo</name_or_title>
      <organization>New York Medical College</organization>
      <phone>914-594-3650</phone>
      <email>mitchell_cairo@nymc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

